On Friday, May 11, 2018, President Trump vowed to fix “the injustice of high drug prices” by announcing the “Blueprint to Lower Drug Prices” (the Blueprint) to address the following challenges:

  1. Excessively high drug prices
  2. Seniors and government programs overpaying for drugs
  3. High out-of-pocket costs for consumers
  4. Lack of transparency in drug pricing
  5. Free-riding by foreign nations as to US investment in innovation

This piece provides analysis of the Blueprint and its proposed reforms.  Read PDF.